Overview

A Study in Subjects With Advanced Solid Tumors

Status:
Active, not recruiting

Trial end date:
2024-02-23

Target enrollment:

Participant gender:

Summary

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Agenus Inc.

Treatments:

Antibodies, Bispecific